MSB 2.51% 97.0¢ mesoblast limited

Ann: Ethics Approval to Treat COVID-19 Patients in Australia, page-188

  1. 291 Posts.
    lightbulb Created with Sketch. 61
    Even though it's double blind and Mesoblast are unlikely to know what the results are yet, the fact that Melbourne and Sydney are now joining the trial... kind of gives a pretty good indication that the upcoming 1st interim read out will not reflect the overwhelming efficacy needed to stop the trial completely. Otherwise no point signing up our cities so late into it if it's going to be stopped anytime soon.

    Writing's on the wall.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.